—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)...
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1...
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire...
COLUMBUS, Ohio and NEW YORK, Dec. 4, 2025 /PRNewswire/ -- Paradigm Health, the technology company rebuilding the clinical research ecosystem,...
Tampa General and Palantir were recognized for their ongoing collaboration to revolutionize care coordination and delivery at the region's only...
PALO ALTO, CALIFORNIA / ACCESS Newswire / December 3, 2025 / Bioz, Inc., the world's leading AI-powered platform for scientific...
Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Officer (CCO) at Cortechs.aiTo strengthen revenue growth of...
IRVING, Texas, Dec. 2, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision...
– Dr. Tagliaferri is a proven executive recognized for advancing innovative therapies across immunology, oncology and other serious diseases –...
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease...
Toronto, Ontario--(Newsfile Corp. - December 1, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light...
Partnership with CHC in Taiwan will pilot SoluPet's flagship Neuronal Defense™ formulation through CHC's veterinary and consumer-health ecosystem TORONTO, ON...
Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation...
New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet...
SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases,...
Panbrain Lume Offers a Drug-Free Path to Deeper Sleep and Faster Sleep Onset in Just 8 Minutes, Now Live on...
One Oral Late Breaking Communication and Two Poster PresentationsNEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp....
KANAZAWA, Japan, Nov. 26, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, report in ACS...
LONDON, Nov. 26, 2025 /PRNewswire/ -- Queen Square Imaging Centre – the world-leading centre treating patients with Essential Tremor and...
Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and managementJoint research to enhance dementia...